Phase III, double-blind, placebo-controlled, crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 antagonist + dexamethasone in patients with germ cell tumors undergoing 5 day cisplatin-based chemotherapy regimen.

Trial Profile

Phase III, double-blind, placebo-controlled, crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 antagonist + dexamethasone in patients with germ cell tumors undergoing 5 day cisplatin-based chemotherapy regimen.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Serotonin 3 receptor antagonists
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Aug 2012 Results published in the Journal of Clinical Oncology.
    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 16 Feb 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top